What Quvit Bio does

Quvit Bio is a South Korea-based (Suwon) life sciences tools company founded in 2019, operating with 1-10 employees in the cells, media, hardware, and consumables segment of biological research products. Its product portfolio comprises biological cells, cell culture media, research hardware equipment, and laboratory consumables distributed to APAC research institutions and pharmaceutical companies, with the value proposition centered on reducing international logistics delays for these time-sensitive biological inputs. The company operates a horizontal go-to-market targeting research customers across South Korea, Japan, and China, with localized technical and sales support as its primary commercial mechanism.

Quvit Bio has been fully acquired by Curi Bio (announced 2026-01-12), and its assets and team have been integrated into Curi Bio Co., Ltd., a newly established wholly-owned subsidiary of Curi Bio in South Korea. This subsidiary functions as the Asia-Pacific commercial and operational hub for the combined entity, delivering cells, media, hardware, and consumables with reduced international logistics delays and enabling APAC access to Curi Bio's proprietary NAM (neuronal activity matrix) technology platform. Distribution operates through direct enterprise field sales via Curi Bio Co., Ltd. across South Korea, Japan, and China. Revenue is generated via hardware sales and consumables, though no pricing model or revenue figures are publicly disclosed. Dr. Wonil Lee, formerly associated with Quvit Bio, was appointed Vice President of Research and Commercialization to lead regional operations post-acquisition.

The company's standalone identity is effectively dissolved following integration into Curi Bio; its independent operations, growth trajectory, and revenue are no longer separately tracked. No AI/ML capabilities are documented in the available source data, and the company website (quvitbio.com) currently resolves to a private WordPress.com placeholder with no public product or technical disclosure.

Name

Quvit Bio

Legal name

Quvit Bio

Website

https://quvitbio.com

Company type

Private

Founded year

2019

Operating status

Acquired

Headcount range

1–10 employees

Short description

Quvit Bio is a South Korea-based life sciences tools company (founded 2019, 1-10 employees) supplying cells, media, hardware, and consumables to APAC research institutions and pharmaceutical companies, now fully integrated into Curi Bio's newly established South Korean subsidiary serving as its Asia-Pacific commercial hub.

Ownership category

akta.pro rank

Product category

Life Science Research Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Laboratory Consumables & Plasticware (Tips, Tubes, Plates, Filters) (HLAGAIAH)

Keywords

• Biological imaging systems
• Cell research products
• Cell culture media
• Research instrumentation
• Lab consumables supply

Headquarters

HQ city

Suwon

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Biology research products (cells, media, hardware, consumables): Quvit Bio, now a wholly owned subsidiary of Curi Bio, generates revenue through the sale of biological research products including cells, media, hardware, and consumables. These products are delivered with reduced international logistics delays following the APAC hub establishment.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Quvit Bio supplies biological research products — cells, cell culture media, research hardware, and laboratory consumables — to research institutions and pharmaceutical companies across South Korea, Japan, and China. Following acquisition by Curi Bio, the company also provides APAC customers with regionalized access to Curi Bio's proprietary NAM (Neural Activity Matrix) technology platform for cell-based analysis and experimentation.

Product overview

Quvit Bio, prior to its full acquisition by Curi Bio, operated as a South Korea-based provider of biological research products including cells, media, hardware, and consumables. The company's product portfolio served customers across South Korea, Japan, and China with localized technical and sales support. Following the acquisition, Quvit Bio's assets and team have been integrated into Curi Bio's new Asia-Pacific subsidiary to deliver these products with reduced international logistics delays. The company also enabled access to Curi Bio's NAM technology platform throughout the APAC region.

Differentiator

Problem solved

Functional benefit

Products and services

• Cells Biological cells for research applications distributed to APAC research institutions and pharmaceutical companies, delivered via localized South Korea-based operations to reduce international logistics delays.
• Media Cell culture media products for supporting cell growth and maintenance in research settings, distributed across South Korea, Japan, and China markets through the APAC hub.
• Hardware Research hardware equipment for cell-based analysis and experimentation, provided to APAC research customers through Curi Bio Co., Ltd.'s regional operational capabilities.
• Consumables Laboratory consumables for cell research workflows, enabling efficient delivery to APAC customers through Curi Bio Co., Ltd.'s localized operations.
• NAM Technology Platform Curi Bio's proprietary NAM (Neural Activity Matrix) technology platform for cell-based analysis, made accessible to customers throughout the APAC region through Quvit Bio's integrated assets and team as part of the Curi Bio Co., Ltd. APAC hub offering.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Cytiva: Global life science tools and bioprocessing provider supplying instruments, media, and consumables. Overlaps with Quvit Bio's research hardware and consumables categories as a broad incumbent with comprehensive APAC operations.
• Thermo Fisher Scientific: Dominant global life sciences tools and lab instruments/consumables supplier with established APAC presence. Competes with Quvit Bio/Curi Bio's full hardware and consumables portfolio as a broad incumbent.
• Lonza: Global bioprocessing and cell-and-gene-therapy manufacturer offering cells, media, and lab services. Operates broadly with overlapping products (media, cells) to Quvit Bio's offering but at much larger scale.
• Agilent Technologies: Global analytical instrument and lab solutions provider with a presence in Korea, Japan, and China. Overlaps with Quvit Bio's research hardware category as a broad analytical-instruments incumbent.

Direct peers

• Corning Life Sciences: Major manufacturer of cell culture media, vessels, and lab consumables used in biological research. Overlaps with Quvit Bio's media and consumables product categories serving the same research customer base.
• Stemcell Technologies: Canada-based supplier of primary cells, cell culture media, and laboratory reagents for life science research. Directly comparable product overlap with Quvit Bio's cells and media offering across research customers.
• Bio-Techne: US-based life sciences company providing reagents, proteins, media, and consumables for biological and biomedical research. Directly comparable in cell culture reagents and research consumables.
• Curi Bio: US-based life-sciences platform developing cells, media, hardware, and consumables for cell-based research, including the NAM technology platform. As Quvit Bio's parent and acquirer, its product line and go-to-market are nearly identical to the offering now distributed through Quvit Bio's APAC hub.

Regional players

• Medipost: Korea-based biotechnology company developing cell and biologics-based products for research and clinical applications. Comparable as a Korean cell/biologics player competing for APAC research customers.
• Bioneer: Korea-based molecular biology and life sciences tools provider offering reagents, instruments, and consumables to research customers in APAC. A regional head-to-head competitor in Korea with overlap to Quvit Bio's product set.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quvit Bio